» Articles » PMID: 33853832

Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 2021 Apr 15
PMID 33853832
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

When recruited to promoters, histone 3 lysine 4 (H3K4) methyltransferases KMT2 (KMT2A-D) activate transcription by opening chromatin through H3K4 methylation. Here, we report that mutations occur frequently in non-small cell lung cancer (NSCLC) and are associated with high mutation loads and poor survival. KMT2C regulated DNA damage responses (DDR) through direct recruitment to DNA damage sites by Ago2 and small noncoding DNA damage response RNA, where it mediates H3K4 methylation, chromatin relaxation, secondary recruitment of DDR factors, and amplification of DDR signals along chromatin. Furthermore, by disrupting homologous recombination (HR)-mediated DNA repair, mutations sensitized NSCLC to Poly(ADP-ribose) polymerase inhibitors (PARPi), whose efficacy is unclear in NSCLC due to low mutation rates. These results demonstrate a novel, transcription-independent role of KMT2C in DDR and identify high-frequency mutations as much-needed biomarkers for PARPi therapies in NSCLC and other cancers with infrequent mutations. SIGNIFICANCE: This study uncovers a critical role for KMT2C in DDR via direct recruitment to DNA damage sites, identifying high-frequency mutations as biomarkers for response to PARP inhibition in cancer.

Citing Articles

YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.

Li X, Zheng M, Ma S, Nie F, Yin Z, Liang Y Leukemia. 2024; 39(2):308-322.

PMID: 39501105 DOI: 10.1038/s41375-024-02451-z.


Microarray analysis points to LMNB1 and JUN as potential target genes for predicting metastasis promotion by etoposide in colorectal cancer.

Liu J, Yang H, Li P, Zhou Y, Zhang Z, Zeng Q Sci Rep. 2024; 14(1):23661.

PMID: 39390002 PMC: 11467296. DOI: 10.1038/s41598-024-72674-8.


Pan‑cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy.

Cao W, Xie Y, Cai L, Wang M, Chen Z, Wang Z Oncol Lett. 2024; 28(3):444.

PMID: 39091583 PMC: 11292467. DOI: 10.3892/ol.2024.14577.


A pan-cancer interrogation of intronic polyadenylation and its association with cancer characteristics.

Liu L, Sun P, Zhang W Brief Bioinform. 2024; 25(5).

PMID: 39082645 PMC: 11289681. DOI: 10.1093/bib/bbae376.


Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3.

Seehawer M, Li Z, Nishida J, Foidart P, Reiter A, Rojas-Jimenez E Nat Cell Biol. 2024; 26(7):1165-1175.

PMID: 38926506 PMC: 11251985. DOI: 10.1038/s41556-024-01446-3.


References
1.
Xu Y, Ayrapetov M, Xu C, Gursoy-Yuzugullu O, Hu Y, Price B . Histone H2A.Z controls a critical chromatin remodeling step required for DNA double-strand break repair. Mol Cell. 2012; 48(5):723-33. PMC: 3525728. DOI: 10.1016/j.molcel.2012.09.026. View

2.
. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

3.
Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z . The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. EMBO Rep. 2019; 20(3). PMC: 6399616. DOI: 10.15252/embr.201846821. View

4.
Shi Y, Jin J, Ji W, Guan X . Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer. 2018; 17(1):99. PMC: 6046102. DOI: 10.1186/s12943-018-0850-9. View

5.
Huang P, Chiu L, Lee C, Yeh Y, Huang K, Chiu C . mSignatureDB: a database for deciphering mutational signatures in human cancers. Nucleic Acids Res. 2017; 46(D1):D964-D970. PMC: 5753213. DOI: 10.1093/nar/gkx1133. View